Cell-in-cell (CIC) structures, in which one living cell is internalized inside another, are prevalent in human tumors. In resectable pancreatic ductal adenocarcinoma (PDAC), Huang et al. (2020) subtyped CICs by multiplex staining and found that heterotypic lymphocyte/macrophage-in-tumor structures (L/MiT) were the only consistently independent adverse prognostic factor across discovery and validation cohorts, with the strongest effect in young women with early-stage disease. The authors explicitly left open whether L/MiT formation is a causal mediator of tumor immune evasion and PDAC progression or a histological correlate (potentially a surrogate of aggressive oncogenic genotype), together with the cellular and molecular pathways by which PDAC tumor cells internalize immune cells, the functional consequences of these events for antitumor immunity, validation in larger independent prospective cohorts, and standardized reproducible CIC detection and scoring. Later literature corroborates the prognostic association and maps the entosis machinery, but mechanistic causal evidence exists only in other cancer types or for homotypic tumor-in-tumor entosis; independent PDAC work shows entosis associates with TP53, KRAS and MYC alterations, supporting but not settling the surrogate alternative; and counter-direction findings (NK-cell 'in-cell killing' of host tumor cells) show heterotypic CIC is not intrinsically immune-evasive. The causal-mechanistic question in PDAC, independent prospective validation of L/MiT, and clinical-grade standardization of CIC detection remain open.

Background

Pancreatic ductal adenocarcinoma (PDAC), the dominant form of pancreatic cancer, carries an overall 5-year survival below 10%. Although 20–30% of cases are resectable at diagnosis, post-operative survival varies widely irrespective of treatment, motivating a search for prognostic biomarkers; the disease is also marked by profound local immune suppression, yet no prognostic marker directly reads immune evasion in situ. A cell-in-cell (CIC) structure is one or more viable cells enclosed inside another cell. The best-characterized formation mechanism is entosis (Overholtzer et al. 2007): the internalizing cell actively invades a neighbor after forming adherens junctions (cadherin-based intercellular adhesions) and constricting an actomyosin 'mechanical ring'; the internalized cell usually dies non-apoptotically. CICs are classified as homotypic (tumor cell inside tumor cell, TiT) or heterotypic (immune cell inside tumor cell or the reverse). Internalized immune cells can die inside tumor cells: cytotoxic lymphocytes taken up by tumor cells undergo granzyme-B-dependent apoptotic death termed 'emperitosis' (Wang et al. 2013), and heterotypic CIC in colon cancer, upregulated by the inflammatory cytokine IL-6, contributes to tumor immune escape (Wang et al. 2019). These observations motivated the hypothesis that heterotypic CIC is a histological readout of active immune evasion, and that CICs can also generate aneuploid, more malignant cells (Chen et al. 2013). Using an 'EML' multiplex immunofluorescence method (E-cadherin for tumor epithelium, CD68 for macrophages, CD45 for leukocytes), Huang et al. (2020) profiled 410 PDAC specimens and subtyped CICs into TiT, lymphocyte-in-tumor (LiT), tumor-in-macrophage (TiM) and macrophage-in-tumor (MiT), with L/MiT denoting LiT plus MiT, i.e., tumor cells as the engulfing partner. Tumor cells were the major engulfer (96.4% of events). Across discovery, validation and combined cohorts, L/MiT was the only variable consistently identified as an independent adverse prognostic factor in multivariable Cox regression (death hazard ratio 1.850, 95% CI 1.175–2.915, p = 0.008 in the discovery cohort, with concordant independent effects in the validation and combined cohorts) and dominated a prognostic nomogram over TNM stage, grade and lymph-node status, with the strongest impact in young women with early-stage (TNM I+II, grade 1+2) disease. The authors proposed subtyped CIC profiling as 'functional pathology', but acknowledged that their data could not distinguish whether L/MiT formation causally suppresses antitumor immunity (for example by killing internalized lymphocytes and macrophages) or merely surrogates an aggressive oncogenic state. Independently and contemporaneously, Hayashi et al. (2020) reviewed roughly 45,000 high-power fields across 516 conventional PDACs in a Memorial Sloan Kettering sequencing cohort and confirmed that entotic CICs are independently associated with poor overall survival, are enriched in liver metastases and poorly differentiated tumors, and are significantly associated with TP53 mutation, KRAS amplification and MYC amplification — strengthening the competing 'genetic surrogate' interpretation without testing causality and without subtyping heterotypic immune-cell-containing CICs. Thus the unresolved question stands: does heterotypic cell-in-cell formation in PDAC causally mediate immune evasion and progression, through which cellular and molecular pathways, and can L/MiT be validated as a clinically usable functional biomarker?

Problem Statement

Determine whether heterotypic cell-in-cell formation in which pancreatic ductal adenocarcinoma cells internalize lymphocytes or macrophages (LiT/MiT, jointly L/MiT) is a causal contributor to immune evasion and disease progression, or a histological correlate — for example a surrogate of the aggressive oncogenic genotype (TP53 mutation, KRAS or MYC amplification) with which entosis associates — and identify the cellular and molecular pathways by which PDAC tumor cells internalize immune cells and determine whether these events have functional consequences for antitumor immunity in physiologically relevant in vivo settings. As the clinical-translation component of the same question — the sense in which the source proposed L/MiT as a 'functional pathology' biomarker — establish the selective prognostic value of L/MiT in independent, larger, prospectively followed and demographically diverse resectable PDAC cohorts beyond the originating group's retrospective series, and develop standardized, reproducible protocols for CIC detection and scoring (multiplex staining, subtype assignment, quantification thresholds) suitable for routine clinical pathology workflows. The causal-mechanistic question is the scientific core: whether L/MiT is a functional readout of immune evasion stands or falls with it, while the validation and standardization components determine whether that readout can be adopted clinically.

References

  1. Huang H, He M, Zhang Y, Zhang B, Niu Z, Zheng Y, Li W, Cui P, Wang X, Sun Q (2020). Identification and validation of heterotypic cell-in-cell structure as an adverse prognostic predictor for young patients of resectable pancreatic ductal adenocarcinoma. Signal Transduction and Targeted Therapy 5:246. doi:10.1038/s41392-020-00346-w. https://doi.org/10.1038/s41392-020-00346-w
  2. Overholtzer M, Mailleux AA, Mouneimne G, Normand G, Schnitt SJ, King RW, Cibas ES, Brugge JS (2007). A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell 131(5):966–979. doi:10.1016/j.cell.2007.10.040. https://doi.org/10.1016/j.cell.2007.10.040
  3. Wang S, He MF, Chen YH, Wang MY, Yu XM, Bai J, Zhu HY, Wang YY, Zhao H, Mei Q, Nie J, Ma J, Wang JF, Wen Q, Ma L, Wang Y, Wang XN (2013). Rapid reuptake of granzyme B leads to emperitosis: an apoptotic cell-in-cell death of immune killer cells inside tumor cells. Cell Death & Disease 4:e856. doi:10.1038/cddis.2013.352. https://doi.org/10.1038/cddis.2013.352
  4. Wang S, Li L, Zhou Y, He Y, Wei Y, Tao A (2019). Heterotypic cell-in-cell structures in colon cancer can be regulated by IL-6 and lead to tumor immune escape. Experimental Cell Research 382(1):111447. doi:10.1016/j.yexcr.2019.05.028. https://doi.org/10.1016/j.yexcr.2019.05.028
  5. Hayashi A, Yavas A, McIntyre CA, Ho YJ, Erakky A, Wong W, Varghese AM, Melchor JP, Overholtzer M, O'Reilly EM, Klimstra DS, Basturk O, Iacobuzio-Donahue CA (2020). Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. Modern Pathology 33(9):1822–1831. doi:10.1038/s41379-020-0549-5. https://doi.org/10.1038/s41379-020-0549-5
  6. Chen YH, Wang S, He MF, Wang Y, Zhao H, Zhu HY, Yu XM, Ma J, Che XJ, Wang JF, Wang Y, Wang XN (2013). Prevalence of heterotypic tumor/immune cell-in-cell structure in vitro and in vivo leading to formation of aneuploidy. PLoS ONE 8(3):e59418. doi:10.1371/journal.pone.0059418. https://doi.org/10.1371/journal.pone.0059418
  7. Su Y, Huang H, Luo T, Zheng Y, Fan J, Ren H, Tang M, Niu Z, Wang C, Wang Y, Zhang Z, Liang J, Ruan B, Gao L, Chen Z, Melino G, Wang X, Sun Q (2022). Cell-in-cell structure mediates in-cell killing suppressed by CD44. Cell Discovery 8:35. doi:10.1038/s41421-022-00387-1. https://doi.org/10.1038/s41421-022-00387-1
  8. Gutwillig A, Santana-Magal N, Farhat-Younis L, Rasoulouniriana D, Madi A, Luxenburg C, Cohen J, Padmanabhan K, Shomron N, Shapira G, Gleiberman A, Parikh R, Levy C, Feinmesser M, Hershkovitz D, Zemser-Werner V, Zlotnik O, Kroon S, Hardt WD, Debets R, Reticker-Flynn NE, Rider P, Carmi Y (2022). Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. eLife 11:e80315. doi:10.7554/eLife.80315. https://doi.org/10.7554/eLife.80315
  9. Choe YJ, Min JY, Lee H, Lee SY, Kwon J, Kim HJ, Lee J, Kim HM, Park HS, Cho MY, Hyun JY, Kim HM, Chung YH, Ha SK, Jeong HG, Choi I, Kim TD, Hong KS, Han EH (2022). Heterotypic cell-in-cell structures between cancer and NK cells are associated with enhanced anticancer drug resistance. iScience 25(9):105017. doi:10.1016/j.isci.2022.105017. https://doi.org/10.1016/j.isci.2022.105017
  10. Fang Q, Yuan J, Zhang X, Lin L (2025). LncRNA MIR31HG facilitates immune escape in head and neck squamous cell carcinoma by promoting heterotypic cell-in-cell formation. American Journal of Cancer Research 15(8):3395–3416. doi:10.62347/MMZP1913. https://doi.org/10.62347/MMZP1913
  11. Song J, Xu R, Zhang H, Xue X, Ruze R, Chen Y, Yin X, Wang C, Zhao Y (2023). Cell-in-cell-mediated entosis reveals a progressive mechanism in pancreatic cancer. Gastroenterology 165(6):1505–1521. doi:10.1053/j.gastro.2023.08.035. https://doi.org/10.1053/j.gastro.2023.08.035
  12. Li K, Li C, Umeda S, Kappagantula RL, Paku M, Zeng Y, Iacobuzio-Donahue C, Yao W (2026). Syndecan-1 is a key mediator of entosis and cellular competition in pancreatic cancer. Pancreas 55(2):e227–e235. doi:10.1097/MPA.0000000000002542. https://doi.org/10.1097/MPA.0000000000002542
  13. Wang R, Zhong H, Wang C, Huang X, Huang A, Du N, Wang D, Sun Q, He M (2023). Tumor malignancy by genetic transfer between cells forming cell-in-cell structures. Cell Death & Disease 14(3):195. doi:10.1038/s41419-023-05707-1. https://doi.org/10.1038/s41419-023-05707-1
  14. Basbous S, Dif L, Dantzer C, Di-Tommaso S, Dupuy JW, Bioulac-Sage P, Raymond AA, Desdouets C, Saltel F, Moreau V (2024). Loss of RND3/RHOE controls entosis through LAMP1 expression in hepatocellular carcinoma. Cell Death & Disease 15(1):46. doi:10.1038/s41419-024-06420-3. https://doi.org/10.1038/s41419-024-06420-3
  15. Wang Y, Niu Z, Zhou L, Zhou Y, Ma Q, Zhu Y, Liu M, Shi Y, Tai Y, Shao Q, Ge J, Hua J, Gao L, Huang H, Jiang H, Sun Q (2021). Subtype-based analysis of cell-in-cell structures in esophageal squamous cell carcinoma. Frontiers in Oncology 11:670051. doi:10.3389/fonc.2021.670051. https://doi.org/10.3389/fonc.2021.670051
  16. Wei Y, Niu Z, Hou X, Liu M, Wang Y, Zhou Y, Wang C, Ma Q, Zhu Y, Gao X, Li P, Gao S, Zhan S, Yang Z, Tai Y, Shao Q, Ge J, Hua J, Gao L, Sun Q, Jiang H, Huang H (2023). Subtype-based analysis of cell-in-cell structures in non-small cell lung cancer. American Journal of Cancer Research 13(3):1091–1102. PMID 37034205, PMC10077035. https://pmc.ncbi.nlm.nih.gov/articles/PMC10077035/
  17. Liu X, Guo R, Li D, Wang Y, Ning J, Yang S, Yang J (2024). Homotypic cell-in-cell structure as a novel prognostic predictor in non-small cell lung cancer and frequently localized at the invasive front. Scientific Reports 14:18952. doi:10.1038/s41598-024-69833-2. https://doi.org/10.1038/s41598-024-69833-2
  18. Wang R, Zhu Y, Zhong H, Gao X, Sun Q, He M (2022). Homotypic cell-in-cell structures as an adverse prognostic predictor of hepatocellular carcinoma. Frontiers in Oncology 12:1007305. doi:10.3389/fonc.2022.1007305. https://doi.org/10.3389/fonc.2022.1007305
  19. Fan J, Fang Q, Yang Y, Cui M, Zhao M, Qi J, Luo R, Du W, Liu S, Sun Q (2020). Role of heterotypic neutrophil-in-tumor structure in the prognosis of patients with buccal mucosa squamous cell carcinoma. Frontiers in Oncology 10:541878. doi:10.3389/fonc.2020.541878. https://doi.org/10.3389/fonc.2020.541878
  20. Zi H, Dai Y, Li M, Wang Y, Wang M, Wang S, Bai Y, Sun J, Fan C, Ding J, Wang T (2025). Correlation of cell-in-cell structure with prognosis in solid tumors — a meta-analysis. BioMed Research International 2025:4943372. doi:10.1155/bmri/4943372. https://doi.org/10.1155/bmri/4943372
  21. Tang M, Su Y, Zhao W, Niu Z, Ruan B, Li Q, Zheng Y, Wang C, Zhang B, Zhou F, Wang X, Huang H, Shi H, Sun Q (2022). AIM-CICs: an automatic identification method for cell-in-cell structures based on convolutional neural network. Journal of Molecular Cell Biology 14(6):mjac044. doi:10.1093/jmcb/mjac044. https://doi.org/10.1093/jmcb/mjac044
  22. Leyba-Mesa MV, Biegański M, Ray E, Młynarczuk-Bialy I, Barkana BD (2026). Quantitative detection of entotic cell-in-cell structures using deformable segmentation and deep learning. Cytometry Part A 109(7):513–531. doi:10.1002/cyto.a.70046. https://doi.org/10.1002/cyto.a.70046
  23. Druzhkova I, Ignatova N, Shirmanova M (2023). Cell-in-cell structures in gastrointestinal tumors: biological relevance and clinical applications. Journal of Personalized Medicine 13(7):1149. doi:10.3390/jpm13071149. https://doi.org/10.3390/jpm13071149
  24. Okuyama K, Fukushima H, Naruse T, Yanamoto S (2023). Cell-in-cell structure in cancer: evading strategies from anti-cancer therapies. Frontiers in Oncology 13:1248097. doi:10.3389/fonc.2023.1248097. https://doi.org/10.3389/fonc.2023.1248097
  25. Liu X, Yang J (2023). Cell-in-cell: a potential biomarker of prognosis and a novel mechanism of drug resistance in cancer. Frontiers in Oncology 13:1242725. doi:10.3389/fonc.2023.1242725. https://doi.org/10.3389/fonc.2023.1242725
  26. Cao Y, Du J, Lai J, Liu C (2026). Cell-in-cell structures and cancer metastasis. International Journal of Surgery 112:12131–12140. doi:10.1097/JS9.0000000000004833. https://doi.org/10.1097/JS9.0000000000004833